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Democratic Republic of the Congo
S U M M A R Y
Background: The reason for the high prevalence of epilepsy in onchocerciasis endemic areas remains
unknown. The aim of this study was to detect risk factors associated with epilepsy in a region endemic
for onchocerciasis.
Methods: In June 2014, a case–control study was performed in Titule, Bas-Uélé Province in the
Democratic Republic of the Congo. Individuals with unprovoked convulsive epilepsy of unknown
aetiology were enrolled as cases (n = 59). Healthy members of families without cases of epilepsy in the
same village were recruited as controls (n = 61). A multivariate binomial logistic regression analysis was
performed to identify potential risk factors associated with epilepsy. To evaluate the potential protective
effect of ivermectin treatment on the development of epilepsy, a nested age-matched case–control study
was performed including only those who were eligible for ivermectin treatment in the year before they
developed epilepsy.
Results: Suspected onchocerciasis skin lesions were more often present in cases than in controls: 12/41
(29%) vs. 1/56 (2%), respectively (odds ratio (OR) 20.26, 95% confidence interval (CI) 2.42–170; p < 0.01).
Ivermectin had been taken 7 months earlier in 29/59 (49%) cases and 29/61 (48%) controls. Onchocerca
volvulus (OV) DNA was detected by PCR in skin snips in 26/34 cases (76%) and 10/14 controls (71%)
(p = 0.7), and there was presence of OV IgG4 antibodies in 35/48 (73%) cases and 15/18 (83%) controls
(p = 0.5). OV DNA was not detected in the cerebrospinal fluid of cases (controls not tested). Both cases
and controls reported frequent bites by blackflies (Diptera, Simuliidae). Bathing daily as opposed to less
often (OR 16.7, 95% CI 2.2–125.8; p < 0.01), bathing between 11 a.m. and 4 p.m. (OR 12.7, 95% CI 1.6–
103.7; p = 0.02), and washing clothes between 11 a.m. and 4 p.m. (OR 10.9, 95% CI 1.5–77.3; p = 0.02)
were all independently associated with epilepsy. Blood screening by specific PCR tests for Toxoplasma
and Wuchereria bancrofti was negative in all cases and controls. A Loa loa infestation was found in only
one case and one control by PCR and Giemsa smear. Antibodies to Taenia solium, Toxocara, and
Trypanosoma sp were not detected in any of the participants. In an age-matched case–control analysis,
16/18 (89%) cases had not taken ivermectin the year before they developed epilepsy, compared to 7/18
(39%) controls that same year (p = 0.002).
Conclusions: These data suggest that frequent activities at rivers known to be blackfly breeding sites and a
historical lack of ivermectin treatment were risk factors for epilepsy in this onchocerciasis endemic area.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The prevalence of convulsive epilepsy is greater in Sub-Saharan
African countries than in high-income countries, and parasitic
infestations are thought to contribute to this increased burden.1,2 A
high prevalence of epilepsy has been reported in many onchocer-
ciasis endemic areas,3,4 and is particularly high in certain localities
in South Sudan, Tanzania, and northern Uganda, where a special
form of atonic epilepsy called ‘nodding syndrome’ (NS) has been
described.5–8 The cause of NS remains unclear,5,9 but case–control
studies have regularly found an association between onchocercia-
sis and NS.5,7,10,11 In a study in Cameroon, the intensity of
infestation with Onchocerca volvulus (OV) was found to be higher in
people with epilepsy than in controls.3
The Democratic Republic of the Congo (DRC) is a country with
large areas where onchocerciasis is still hyperendemic.12 Between
April 2014 and June 2014, several epilepsy prevalence studies were
performed in villages in the Bas-Uélé Province, namely Liguga,13
Dingila, and Titule14 (Figure 1). Among the 12 776 people in Dingila,
373 (2.9%) individuals with epilepsy were identified. In a door-to-
door survey in Titule, 68 (2.3%) of the 2908 people who participated in
the survey were found to present episodes of epilepsy.14 In Titule,
epilepsy showed a marked spatial pattern, with clustering of cases
occurring within and between adjacent households. The individual
risk of epilepsy was found to be associated with living close to the
BimaRiver,a fastflowingriverwhereblackflies(Diptera: Simuliidae)–
the vector of OV – oviposit and breed.14 The degree of onchocerciasis
endemicity in Titule was not estimated in 2014, but in 1999, during
a rapid epidemiological mapping of onchocerciasis (REMO) survey,
all of the 33 persons examined in the village had nodules. As a
consequence, ivermectin has been distributed in Titule once a yearFigure 1. Location of Titule in the Bas-Uele dito persons over 5 years of age, but not to pregnant or breastfeeding
women, since 2000. The coverage initially was reported to be 23%,
but the coverage has increased over the years to 73–81% of the
eligible individuals (F. Tepage, personal communication).
During the epilepsy prevalence survey in Titule, a case–control
study was also performed to investigate whether exposure to
Simulium spp blackflies is indeed a risk factor for developing
epilepsy and to determine whether treatment with ivermectin
may protect against developing epilepsy.
2. Materials and methods
2.1. Setting
Titule, a locality crossed by the Bima River, has a population of
11 882 inhabitants. Our visit to Titule was announced by the local
doctor and the volunteers of the ‘relais communautaire’. These are
villagers making up the community surveillance network, who are
involved in the community-directed treatment with ivermectin
campaigns (CDTI), vaccination campaigns, and mosquito net
distribution; therefore they know the members of their commu-
nity well. On arrival, at least 50 patients were waiting for us.
During our stay in Titule at least 100 additional patients wanted to
be seen by us. Two patients with epilepsy did not want to
participate in the study because they did not want to undergo a
lumbar puncture, a procedure included in the study protocol. No
incentives were given to the patients to participate.
2.2. Design
The first 59 patients with confirmed active epilepsy after
examination by one of the study doctors and who agreed tostrict, Democratic Republic of the Congo.
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Active epilepsy was defined as a patient who had presented at least
two unprovoked seizures of unknown origin in the last 12 months.
With regard to the seizures, mainly tonic–clonic generalized
seizures and episodes of absence of sudden onset and of brief
duration were considered.
Controls were healthy volunteers from families without any
cases of epilepsy, chosen from the same village among individuals
of the same age and sex groups.
2.3. Procedures
After written informed consent was obtained, the person with
epilepsy or the healthy control, or their parent/guardian, was
interviewed in their native language by Congolese physicians (MM,
GMa, GMu) and local nurses (FM, BY) using a standardized
questionnaire. This questionnaire included questions on ethnicity
of the mother and the father, movement of the family in the past,
time spent at the major river (bathing, fishing, fetching water,
washing clothes), episodes of stay in temporary settlements along
rivers or in the forest, frequency of insect bites, exposure to
domestic animals, the consumption of insects and larvae, year of
onset of the epilepsy, years of ivermectin intake, and history of
febrile convulsions (defined as seizures in children <5 years old,
associated with fever, without an underlying cause). For cases,
exposure to the potential risk factors in the period before they
developed epilepsy was assessed, while for controls, potential risk
factors immediately prior to the interview were assessed.
After the interview, cases and controls were examined by a
physician (GM, MM, GMa, RC). On physical examination, cases and
controls were assessed for onchocerciasis nodules, skin abnormal-
ities, vision, and mental status. Height and weight were measured
using a stadiometer and a digital scale and these measurements
were used to calculate the body mass index (BMI, kg/m2). Visual
acuity was mainly assessed by history taking and not by a formal
ophthalmological examination. A blind person was considered a
person who had no light perception.
Blood samples were collected from all cases and controls in
heparinized collection vials and adsorbed on Serobuvard. A malaria
antigen test (SD BIOLINE Malaria Ag P.f) was only performed in the
cases, and Giemsa smears for the presence of Loa loa were
performed in a batch of cases and controls. Because of time
restrictions, physical examinations and laboratory tests could not
be performed for all patients.
A skin snip was taken from the left and right iliac crests of all
subjects with a Holtz corneoscleral punch (2 mm) and stored in
90% ethanol to be tested for OV using an in-house PCR method
(Supplementary Material, supplemental methods). Cases were
examined neurologically, and if there were no contraindications
(no focal neurological deficit and no clinical signs of increased
intracranial hypertension), a cerebrospinal tap was performed and
cerebrospinal fluid (CSF) obtained. All lumbar punctures were
performed by a single physician (GMu), who had received special
training in neurology while working as a medical doctor in a
trypanosomiasis treatment programme. After the procedure,
patients were able to rest and received paracetamol.
Blood specimens were screened using an in-house PCR for
molecular evidence of OV, Onchocerca ochengi, L. loa, Mansonella
spp, Wuchereria bancrofti, and Toxoplasma gondii (see Supplemen-
tary Material, supplemental methods). Serological tests were also
performed targeting OV IgG4 antibodies (Ov16 Standard Diag-
nostics, Inc., Alere SD BIOLINE, Gyeonggi-do, Republic of Korea),
Taenia solium antibodies by immunoblot assay (LDBIO Diagnostics,
Lyon, France), Trypanosoma brucei antibodies by immunofluores-
cence test, and Toxocara canis antibodies by enzyme immunoassay
(Bordier Affinity products SA, Crissier, Switzerland). Skin snips andCSF were also screened for OV DNA by in-house PCR assay. In skin
snips of 19 cases and 35 controls, the Wolbachia ftsZ gene was
quantified from purified DNA by real-time PCR (qPCR) (see
Supplementary Material, supplemental methods).
Participants with a positive malaria antigen test received anti-
malaria treatment (artemether and lumefantrine). All patients who
had not received ivermectin the previous year were offered a dose
of ivermectin. A stock of anti-epileptic drugs (phenobarbital) was
handed over to the local health centre.
2.4. Statistical analyses
Factors describing the properties of the case and control
populations (weight, height, BMI, clinical symptoms, and potential
risk factors such as contact with insects, domestic animals, and
rivers) were assessed by age-adjusted univariate models (linear
regression for factors measured on a continuous scale, or else
binomial logistic regression) to identify significant differences in
the properties of the two groups.
Participants were not asked about their contact with insects
and domestic animals before epilepsy appeared, but whether or
not they currently experienced exposure. However for factors
concerning exposure to rivers (e.g., through washing clothes and
bathing), participants were specifically asked about exposure
before the onset of the epilepsy. Therefore, in a multivariate
binomial logistic regression analysis, only variables assessing
exposure to rivers were included to identify significant associa-
tions with epilepsy status. Factors with a p-value of 0.5 or more
from the univariate analysis were discarded from this multivariate
analysis, as this suggested they were highly likely not to be
significantly associated. A minimum adequate model was obtained
using backwards stepwise selection to identify which of the factors
describing river exposure conferred the greatest explanatory
power. Chi-square statistics and associated p-values were calcu-
lated for each nested version of the model arising from the deletion
of each individual term, and the term missing from the model with
the highest p-value was deleted from the model. This was repeated
until no further factors could be removed that would not cause a
significant decrease in the explanatory power of the model.15 The
age adjustment was maintained through this reduction process.
For each risk factor, age-adjusted odds ratios (OR) and respective
95% confidence intervals (CI) were estimated. Finally, it was
attempted to minimize the possibility that any factor associated
with an increased risk of epilepsy was actually associated with an
increased risk of onchocerciasis of which epilepsy was just one
possible symptom. Hence, the stepwise selection procedure was
run again and a new minimum adequate model generated,
adjusted for onchocerciasis, with individuals (both cases and
controls) classified as onchocerciasis-positive if they showed any
evidence of onchocerciasis, either clinical or laboratory-based.
In each year from 2000 to 2013, the proportion of cases and
controls eligible to receive ivermectin treatment (i.e., 5 years old or
more) who received treatment was calculated. In order to identify
differences in treatment history in cases and controls, these time-
series were compared using a univariate binary logistic regression
model adjusted by year. To minimize the chances that any difference
detected was actually attributable simply to a difference in
prevalence of onchocerciasis, this model was run a second time
including only those individuals (both cases and controls) who could
be classified as onchocerciasis-positive by laboratory-based criteria
(OV PCR skin snip positivity and/or OV IgG4 antibody positivity).
The relationship between infection status with parasites and
epilepsy status was assessed using univariate binary logistic
regression models.
Analyses were performed using the R statistical computing
package.16
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Fifty-nine cases with epilepsy and 61 controls were enrolled in
the study. The sex distribution was similar in the cases and
controls: males made up 47% of the case population and 46% of the
control population. The control population had an older median
age of 16 years in comparison to 15 years for the cases. The age
distributions are shown in Figure 2.
Cases and controls were similar concerning ethnicity of the
parents (Boa and Zande were the most frequent ethnicities,
represented by 56% and 28% of cases and 49% and 30% of
controls, respectively) and place of residence and birth (mainly
Titule, >97% of cases and controls being residents, 71% of
cases and 57% of controls having been born there). More parents
of cases were born in Titule compared with controls (39% in
cases, 22% in controls; univariate binomial logistic regression,
OR 2.30, p = 0.04). Cases and controls did not differ in the
distribution of the main money-generating activities of their
family (mainly agriculture). Cases had typically spent 1 year
less in primary school (only 3 years compared to 4 years for
controls).
3.1. Clinical characteristics
There was a history of tonic–clonic seizures in 58 (98%) cases,
with drooling in 41 (70%) and urinary incontinence in 34 (57%).Figure 2. Histograms showing age di
Table 1
Clinical characteristics of cases and controls
Clinical characteristics Cases (n = 59) 
Body weight (kg), mean (SD) 38.9 (11.21) 
Height (cm), mean (SD) 148.4 (15.03) 
BMI (kg/m2), mean (SD) 17.83 (2.86) 
Itching 65% (26/40) 
Onchocerciasis suspected skin lesions 29% (12/41) 
Abnormal vision 8% (4/52) 
Blindness 2% (1/59) 
Nodules 8% (3/40) 
Burn scars 18% (10/57) 
History of febrile convulsions 21% (12/56) 
OR, odds ratio; CI, confidence interval; SD, standard deviation; BMI, body mass index.
a Age-adjusted linear regression model.
b Age-adjusted binomial logistic regression model.
c OR not calculated due to null value in one or more classes.Absence seizures were reported in 18 (31%), in all but one of whom
there was also a history of tonic–clonic seizures. Neuropsychiatric
abnormalities were present in 18 (31%), with severe cognitive
impairment. Spatial disorientation was noted in 12 (20%) and
temporal disorientation in 13 (22%); 14 (24%) regularly got lost in
the village. Nineteen (33%) had problems in speaking, and episodes
of hallucinations were reported in 19 (32%). Three (5%) showed
stunted growth and a lack of secondary sexual characteristics (one
of them was a boy, 16 years old, 21 kg, 128 cm, without pubic hair).
The mean age at onset of epilepsy was 12 years (interquartile range
9–14 years, range 2–37 years). Mean body weight, height, and BMI
were significantly lower in cases than in controls (Table 1). Cases
were more likely to present with onchocerciasis-associated
symptoms, to have burn scars, and to have a history of febrile
convulsions.
3.2. Potential risk factors associated with epilepsy
Nearly all cases and controls reported exposure to Simuliidae
(called ‘Mbitiri’ in the local language) (Table 2). Exposure to
Culicoides spp (called ‘invisibles’) and eating insects was more often
reported by controls. Contact with chickens, pigs, and goats was
more often reported by controls. On the other hand, daily bathing
was more frequently reported by cases. In particular, day time
bathing and washing (11 a.m.–4 p.m.) were more frequently
reported by cases.stribution of cases and controls.




16% (8/51) 13.31 (4.34–40.8) <0.01b
2% (1/56) 20.26 (2.42–170) <0.01b
0% (0/52) -c -c
0% (0/61) -c -c
4% (2/46) 1.13 (0.14–9.3) 0.9b
0% (0/61) -c <0.01
3% (2/61) 8.23 (1.74–38.8) <0.01b
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analysis was performed on a subset of individuals who reported
washing and bathing at any time (Table 3). This reduced the
dataset to 54 individuals, but maintained a balance of 54% controls
and 46% cases. This analysis showed that bathing daily and bathing
between 11 a.m. and 4 p.m. were independently associated with
epilepsy.
Whilst maintaining the age adjustment, a minimal model was
obtained containing daily bathing (OR 16.7, 95% CI 2.2–125.8;
p < 0.01) and bathing in the daytime (OR 12.7, 95% CI 1.6–103.7;
p = 0.02), both previously significant in the full multivariate model,
and also washing clothes in the daytime (OR 10.9, 95% CI 1.5–77.3;
p = 0.02), previously marginally non-significant. All three may be
seen as proxies for the frequency and intensity of contact with
blackflies.
3.3. Ivermectin treatment history
The percentage of patients receiving ivermectin was found to be
significantly lower in cases than in controls (univariate binomial
generalized linear model (GLM) adjusted by year, p = 0.03), and
this relationship was maintained when considering only patientsTable 2
Potential risk factors associated with epilepsya
Factor Cases 
Contact with insects
Contact with Simuliidae 96% (55/57) 
Contact with Culicoides 71% (41/57) 
Contact with Chrysops 82% (47/57) 
Contact with tsetse 19% (11/57) 
Eating insects 75% (43/57) 
Eating larvae 82% (47/57) 
Contact with domestic animals
Cat 4/57 (7%) 
Dog 4/57 (7%) 
Chicken 21/57 (37%) 
Cow 0/57 (0%) 
Pig 0/57 (0%) 
Goat 6/57 (11%) 
Contact with rivers
Bathing: never (reference value) 33% (17/51) 
Bathing: less than daily 20% (10/51) 
Bathing: daily 47% (24/51) 
Washing clothes: never (reference value) 25% (13/55) 
Washing clothes: less than daily 62% (34/55) 
Washing clothes: daily 15% (8/55) 
Bathing 5 a.m.–10 a.m. 40% (23/58) 
Bathing 11 a.m.–4 p.m. 58% (34/58) 
Bathing 5 p.m.–10 p.m. 36% (21/58) 
Washing clothes 5 a.m.–10 a.m. 38% (21/56) 
Washing clothes 11 a.m.–4 p.m. 63% (35/56) 
Washing clothes 5 p.m.–10 p.m. 23% (13/56) 
OR, odds ratio; CI, confidence interval.
a ORs and p-values estimated from age-adjusted univariate binomial logistic regressio
values in one of the groups. In the case of bathing and washing times, the comparison
b OR not computed as there were no records in the case group.
Table 3
Age-adjusted multivariate binomial logistic regression analysis of contact with the rive
Factor Cases 
Bathing daily (reference less than daily) 47% (24/51) 
Washing clothes daily (reference less than daily) 15% (8/55) 
Bathing 5 a.m.–10 a.m. 40% (23/58) 
Bathing 11 a.m.–4 p.m. 58% (34/58) 
Washing clothes 5 a.m.–10 a.m. 38% (21/56) 
Washing clothes 11 a.m.–4 p.m. 63% (35/56) 
aOR, age-adjusted odds ratio; CI, confidence interval.who had positive onchocerciasis laboratory test results (univariate
binomial GLM adjusted by year, p = 0.01) (Figure 3).
Eighteen age-matched case–control pairs were available in the
dataset. Sixteen (98%) cases did not take ivermectin the year before
they developed epilepsy, compared to seven (39%) controls that
same year (p = 0.002).
3.4. Laboratory results
OV DNA was detected by PCR in skin snips with similar
frequency in both cases (76%) and controls (71%); in 73% of cases
and 83% of controls there was also presence of OV IgG4 antibodies
(Table 4). In none of the cases was OV DNA detected in the CSF.
Mansonella spp were frequently found in cases and controls, while a
L. loa infestation was found in only one case and one control.
There was no difference in the quantity of Wolbachia genes per
microfilaria between cases and controls. PCR screening of blood for
O. ochengi, T. solium, T. gondii, and W. bancrofti were all negative.
Toxocara and T. solium antibodies were absent in all participants; T.
brucei antibodies were slightly increased in one case and one
control. A malaria test was positive in 33/44 (77%) cases, but was
not performed in controls.Controls OR (95% CI) p-Value
98% (60/61) 0.46 (0.04–5.20) 0.5
86% (53/61) 0.39 (0.15–1.00) 0.05
72% (44/61) 1.84 (0.15–1.00) 0.18
21% (13/61) 0.88 (0.36–2.19) 0.80
98% (59/60) 0.05 (0.01–0.42) <0.01
100% (60/60) 0.00 (0.00–Inf) 0.99
5/41 (12%) 0.55 (0.14–2.20) 0.4
2/41 (5%) 1.48 (0.26–8.52) 0.7
24/41 (59%) 0.42 (0.18–0.95) 0.04
2/41 (5%) -b 0.17c
4/41 (10%) -b 0.03c
13/41 (32) 0.25 (0.09–0.73) 0.01
40% (22/55)
38% (21/55) 0.62 (0.23–1.65) 0.34
22% (12/55) 2.59 (1.01–6.62) 0.05
22% (12/55)
76% (42/55) 0.75 (0.3–1.85) 0.53
2% (1/55) 7.31 (0.8–68.1) 0.08
22% (13/58) 2.25 (0.98–5.01) 0.06
28% (16/58) 3.86 (1.76–8.47) <0.01
36% (21/58) 0.94 (0.44–2.04) 0.90
52% (29/56) 0.55 (0.26–1.17) 0.12
38% (21/56) 2.71 (1.24–5.89) 0.01
13% (7/56) 2.01 (0.73–5.58) 0.18
n, except for those labelled ‘c’, where a Fisher’s exact test was performed due to null
 is with those who bathed or washed but at other times.
r as a potential risk factor for epilepsy
Controls aOR (95% CI) p-Value
22% (12/55) 16.33 (1.99–134.2) 0.009
2% (1/55) 1.07 (0.07–16.6) 0.96
22% (13/58) 3.28 (0.49–22.1) 0.22
28% (16/58) 22.65 (1.77–289.3) 0.016
52% (29/56) 1.67 (0.27–10.5) 0.58
38% (21/56) 9.78 (0.93–103.1) 0.058
Figure 3. Percentage of patients who were eligible to receive Ivermectin, that were recorded to have taken it in each year 2000-2013. This is shown for all patients (left) and
only for patients with documented OV infestation (right).
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This is the first case–control study in the DRC with the aim of
detecting risk factors for the development of epilepsy in an
onchocerciasis endemic region. The most important finding of this
study is that cases reported a more frequent contact with the river.
Two proxies for the frequency and intensity of exposure to
blackflies were risk factors for developing epilepsy. The reason why
being at the riverside between 11 a.m. and 4 p.m. was a risk factor
for epilepsy is less clear. Indeed most members of the Simulium
damnosum complex have a bimodal daily biting pattern, with a
peak in the morning (7 a.m. to 9 a.m.) and another peak in the
afternoon (4 p.m. to 6 p.m.).17 In the present study, bathing
between 5 a.m. and 10 a.m. was slightly more often reported in
cases than controls (p = 0.06). Respondents were not asked about
exposure to the river between 4 p.m. and 6 p.m. Biting patterns can
also vary with cytospecies, and a unimodal (middle-of-the-day)
pattern is known within the S. damnosum complex, and is more
likely to be found in forest areas than in savannah areas.
Given that exposure to blackfly bites is very frequent in Titule,
and greatest for those spending the most time at the riverside, this
suggests a potential role for blackflies either in transmitting an
agent or triggering an immune response that may cause epilepsy.
A case–control study performed at five Health and Demograph-
ic Surveillance System centres in Sub-Saharan Africa demonstrated
that exposure to multiple parasites was associated with active
convulsive epilepsy. Particularly, individuals with antibodies to
O. volvulus (OR 1.98, 95% CI 1.52–2.58; p < 0.001), T. canis (OR 1.52,
95% CI 1.23–1.87; p < 0.001), and T. gondii (OR 1.28, 95% CI 1.04–
1.56; p = 0.018) were more likely to have active convulsive
epilepsy.18 In the present study, it was found that cysticercosis,
Toxocara infestation, and trypanosomiasis cannot explain the high
prevalence of epilepsy in the region.Table 4
Laboratory test results for cases and controls
Test Cases Controls p-Value
Skin OV PCR-positive 26/34 (76%) 10/14 (71%) 0.7
OV IgG4 antibodies 39/49 (78%) 15/18 (83%) 0.5
Mansonella spp
(PCR on buffy coat)
12/49 (78%) 13/20 (65%) 0.91
Loa loa (PCR blood and
Giemsa smear)
5% (1/20) 4% (1/26) 0.9
OV, Onchocerca volvulus.Skin lesions suggesting an onchocerciasis infestation were
more often present in cases than in controls. Five patients with
epilepsy presented with a leopard type of skin. However, OV DNA
was detected in skin snips in an equal percentage of cases and
controls (in 76% of cases and in 71% of controls). OV DNA was not
detected in the CSF of cases (controls not tested). The latter is
similar to the finding of a study performed in Tanzania.19,20 The
former is in contrast with other case–control studies that have
found OV microfilaria to be present more often in cases compared
to controls.4,7,21 However, previous case–control studies investi-
gating the association between epilepsy and onchocerciasis were
performed in populations prior to the introduction of ivermectin.
In the present study, nearly 50% of cases and controls received
ivermectin 7 months before the skin snip examination. The
equal percentage of cases and controls with OV IgG4 antibodies is
also in contrast with other case–control studies, which have
shown a higher percentage of OV IgG4 antibodies in cases.10 The
explanation for the discrepancy between clinical and laboratory
onchocerciasis findings could be that cases became infected
earlier and/or acquired a higher degree of infestation than
controls, particularly in the period before they developed
epilepsy. This is suggested by the presence of leopard-type skin
lesions only in the cases. Such lesions are sequelae of a severe
cumulative OV infestation in the past.22,23 In a case–control
study performed in December 2015 in Drazu, a village in Ituri
Province, where ivermectin had never been distributed, persons
with epilepsy were significantly more often infested with OV
and had a higher microfilariae load than random selected
age-matched village controls without epilepsy (data not yet
published).
Mansonella spp infestation was very frequent in cases and
controls. Exposure to Ceratopogonidae (Culicoides spp, vector of
Mansonella spp) was also very frequently reported by cases and
controls, but slightly more often by controls than cases. A higher
prevalence of Mansonella perstans infestation has been found in
a NS case–control study performed in South Sudan.7 However,
M. perstans infestations have so far been considered not to cause
any serious illness.24
Cases had a lower body weight, height, and BMI than controls.
Moreover, three cases presented with important stunted growth
and with a lack of secondary sexual characteristics. This has also
been reported in case–control studies on NS.25 However the lower
body weight and BMI and the clinical signs of onchocerciasis can
also be explained by a selection bias, because controls were
required to be healthy.
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and controls, even if comparisons are made only between
individuals with evidence of having onchocerciasis. This finding
is an additional argument that part of the epilepsy in onchocercia-
sis endemic regions is caused directly or indirectly by the OV
infestation. It further suggests that the use of ivermectin may
protect against the development of epilepsy as a comorbidity of
onchocerciasis.
How an OV infestation could lead to epilepsy remains unclear.
Indeed, OV microfilariae are only rarely found in the nervous
system.20 In Tanzania, similar to this study, PCR tests on the CSF
of patients with NS and epilepsy with other seizure types failed
to identify OV DNA.20 A recent study showed that 11/19 (58%)
patients with NS had detectable serum autoantibodies to
leiomodin 1 (a protein present in certain neurons) compared to
5/19 (26%) controls (matched OR 7.0, 95% CI 0.9–11.1).26 These
antibodies, also present in the CSF of patients with NS, were found
to be neurotoxic in vitro and cross-reacting with OV-specific
proteins.26 In a recent study in Uganda, serum antibodies against
voltage-gated potassium channel (VGKC) complex proteins were
detected in 15 (48%) of 31 patients with NS compared to only one
(9%) of 11 sibling controls.27 However, whether these autoanti-
bodies are the cause of the NS or the consequence of damage to
the neurons caused by another mechanism28 remains to be
investigated.
NS, and convulsive epilepsy without NS, often occur in the same
families in onchocerciasis endemic areas and are therefore
probably caused by the same pathological process.29 If convulsive
epilepsy without NS is also caused by an antibody response to OV-
specific proteins, one would then expect a high prevalence of
epilepsy in all onchocerciasis hyperendemic regions.
Cases more often reported a history of febrile convulsions. This
confirms the observation of others that febrile convulsions may be
associated with epilepsy later in life.30 Families of cases were less
likely to consume fried insects and larvae and were less likely to
have domestic animals such as chickens, pigs, and goats, compared
with controls. This finding may be the consequence of the epilepsy.
Indeed, in Titule it is believed that persons with epilepsy should
not eat termites, caterpillars, chicken, pork, or goat (F. Tepage,
personal communication). It has also been suggested that if
humans are bitten by blackflies infected by O. ochengi (the cause
of onchocerciasis in cattle, but non-pathogenic for humans), they
may develop O. ochengi antibodies that provide a degree of
immunity against OV.31 Whether a similar phenomenon may occur
with goats infested by Onchocerca is unknown.31 It also may be
that families of persons with epilepsy own fewer animals and are
poorer than families without persons with epilepsy.
This study has several limitations. First the team did not include
a neurologist, and a validated neuropsychological instrument was
not used to assess patients with epilepsy. Therefore it was not
possible to provide a detailed description of the different forms of
epilepsy and the cognitive abnormalities. Second, although cases
and controls were chosen among the same age and sex groups, only
18 cases and controls were individually matched for age. Third,
cases were asked about their activities before they developed
epilepsy and controls about their current activities. Fourth,
interviewers were aware of the epileptic status of the participants.
However, all questions were asked with great caution so as not to
elicit certain answers. Finally, because of time constraints, physical
examinations and laboratory tests were not performed for all cases
and controls and less frequently for healthy controls. Moreover,
certain examinations such as parasitological stool examinations
were not performed at all.
In conclusion, despite these limitations, this case–control study
shows that frequent activities at rivers known to harbour blackflies
and a historical lack of ivermectin treatment were associated withthe presence of epilepsy. The study results indicate that future
studies looking at the aetiology of epilepsy need to focus on
questions around exposure to rivers and blackflies, the degree of
onchocerciasis endemicity, and the intake of ivermectin.
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